Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.

Abstract: Featured are methods of diagnosing and treating liver disease.

Abstract: The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.

Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.

Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Abstract: The present invention is based, in part, on the identification of methods of using multiple-variable interleukin-2 (IL-2) doses for identifying, assessing, preventing, and treating immune disorders.

Abstract: This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.

Abstract: The present invention provides compositions and methods of treating various disorders associated with aberrant cell growth.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.

Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.

Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP domain containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.

Abstract: The present invention provides methods for determining the level or status of minimal residue disease (MRD) in a multiple myeloma (MM) patient including analyzing peripheral natural killer (NK), NK-T and T cell distribution and/or activation, and quantifying inflammatory cytokines, chemokines and growth factors in a biological sample obtained from an MM patient to provide a peripheral immune profile; and obtaining a level or status of MRD in the MM patient from the peripheral immune profile, wherein if the peripheral immune profile exceeds a pre-determined threshold, the MM patient is positive for MRD.

Abstract: This invention relates to methods for treating subjects with breast cancer, based on tumor expression levels of chemokines.